Research & Education

Mesothelioma: Causes, Prevention, Screening and Early Detection

November 15, 2016 at 9:00PM EST - Recording Available

Name of Reviewer(s): 


Laurie Gaspar, MD –Nothing to Disclose

Name of Planner(s): 


Pia Hirsch-Nothing to Disclose      Carlos Ferreira-Nothing to Disclose

Name of Activity: 


Mesothelioma: Causes, Prevention, Screening and Early Detection

Date of Activity:




COI Resolution: Ensure a balanced discussion of alternative. Do not use trade names. Do not refer to company names or logos. Do not recommend therapies.

“All planning committee members’ and/or faculty’s identified conflicts of interest pertaining to this activity were resolved prior to the activity.”

Speaker: Harvey I. Pass, MD:

Grant/Research Support from:

NCI/NIH, NHLBI, CDC, DOD, Belluck and Fox, NYU Cancer Center, Patient Philanthropy, Genentech,


Honoraria from:

Astra Zeneca, IASLC, AATS


Speaker: Michele Carbone, MD-Nothing to Disclose  

Type of Activity:

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?


If yes, please list: Unrestricted educational grant support by Bayer.


Financial/Commercial and Conflists of Interest Disclosures

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

About the Program:

A recent IASLC webinar (July 27, 2016 - available on demand at addressed the role of surgery for malignant mesothelioma and updated the status of systemic therapy of this disease.  Despite advances in treatment, this disease remains a formidable challenge.  Clinical research efforts focusing on prevention and intervention at earlier stages of the disease process may improve the management of mesothelioma.

Following the presentation, there will be ample time for discussion and a question/answer session.  Attendees will be able to submit questions and comments to the faculty via internet chat.

This sixty-minute webinar will feature 2 presentations:

Mesothelioma Causes and Prevention - Michele Carbone, MD

In this program, Dr. Michele Carbone will examine the causes of mesothelioma and potential prevention strategies.

The Role of Biomarker Screening to Identify Asbestos Exposed Individuals and Among Them Those who Have Developed Mesothelioma - Harvey I. Pass, MD

Dr. Harvey Pass will discuss how blood based biomarkers can be used for early detection of mesothelioma and explain the role of biomarkers to determine mesothelioma prognostication.

Please complete the evaluation link provided to you after the activity. The certificate of credit will be ready for you to print or save for your records.


  • Define what is asbestos and how it causes cancer
  • Describe the role of genetics in mesothelioma
  • Assess the demographic differences among asbestos induced mesothelioma versus genetic or environmentally induced mesotheliomas
  • Discuss potential mesothelioma prevention strategies


  • Provide state-of-the art definitions of asbestos and mesothelioma
  • Explain the role of biomarker screening to identify asbestos exposed individuals and among them, those who have developed mesothelioma,
  • Describe the role of genetics in mesothelioma
  • Identify potential mesothelioma prevention strategies

What BARRIERS Learner will encounter:

  • Mesothelioma remains an intractable disease, survival outcomes for both early and advanced stages of disease  range from 12-25 months, thus there is significant nihilism towards this disease among community-based clinicians
  • Initiatives focusing on epidemiology, prevention, screening and early detection and systemic treatment are not yet supported by a level of clinical evidence that would change standard management of patients outside of investigational settings

How does the activity ADDRESS THE BARRIERS:

This activity reports on the scientific and clinical research focused on screening and early detection of mesothelioma. With knowledge and awareness of these efforts and a contemporary view of clinical data, the ultimate clinical adoption of such strategies will be accelerated to the benefit of patients and towards more favorable prognosis.

This activity will:

  • Assess the progress of mesothelioma clinical research in the areas of causation, prevention, screening, and early detection
  • Provides an understanding of the state –of-the- art of the role of biomarker screening to identify asbestos exposed persons and those who develop mesothelioma
  • Introduces novel concepts of potential mesothelioma prevention strategies


Registration is on a first-come, first-served basis. Participation is limited.

How to use the Time Zone Converter